Abstract

PurposeTo investigate the agglomeration behaviour of the fine (<5.0 μm) and coarse (>12.8 μm) particle fractions of salmeterol xinafoate (SX) and fluticasone propionate (FP) by isolating aerodynamic size fractions and characterising their physicochemical and re-dispersal properties.MethodsAerodynamic fractionation was conducted using the Next Generation Impactor (NGI). Re-crystallized control particles, unfractionated and fractionated materials were characterized for particle size, morphology, crystallinity and surface energy. Re-dispersal of the particles was assessed using dry dispersion laser diffraction and NGI analysis.ResultsAerosolized SX and FP particles deposited in the NGI as agglomerates of consistent particle/agglomerate morphology. SX particles depositing on Stages 3 and 5 had higher total surface energy than unfractionated SX, with Stage 5 particles showing the greatest surface energy heterogeneity. FP fractions had comparable surface energy distributions and bulk crystallinity but differences in surface chemistry. SX fractions demonstrated higher bulk disorder than unfractionated and re-crystallized particles. Upon aerosolization, the fractions differed in their intrinsic emission and dispersion into a fine particle fraction (<5.0 μm).ConclusionsMicronized powders consisted of sub-populations of particles displaying distinct physicochemical and powder dispersal properties compared to the unfractionated bulk material. This may have implications for the efficiency of inhaled drug delivery.

Highlights

  • Dry Powder Inhaler (DPI) formulations generally consist of micronized drug (

  • Powder deposits were recovered from the Next Generation Impactor (NGI) pre-separator and stages 1–7 for salmeterol xinafoate (SX) and stages 1–6 for fluticasone propionate (FP) when the samples were fractionated according to their aerodynamic particle size

  • Whereas previously the geometric particle size of powder fractions recovered from stages 1–6 of the NGI following fractionation were sequentially smaller [26], it was postulated that in the current study SX powder depositing in the pre-separator and stages 1–4 remained agglomerated

Read more

Summary

Introduction

Dry Powder Inhaler (DPI) formulations generally consist of micronized drug (

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call